Payment overview · 2025
General Payments
$695.79
37 reported records · 16 companies
Healthcare provider profile · identity verified
Kent Willis, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PLEASANT GROVE, UT · NPI 1114306131
Verified facts
What the public records show
CMS Open Payments records show Kent Willis, D.O. received $695.79 in general payments during 2025 across 37 reported records.
ABBVIE INC. accounted for 38.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $266.51 | 38.3% | 15 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $60.00 | 8.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.86 | 8.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $43.98 | 6.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.99 | 4.9% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.84 | 4.9% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $28.75 | 4.1% | 1 | 2025 |
| Neuronetics, Inc. | Unresolved — no canonical attribution shown | $22.49 | 3.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.32 | 3.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.41 | 2.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.28 | 2.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.81 | 2.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.38 | 2.5% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $16.96 | 2.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.13 | 2.3% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.08 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $635.79 | 36 |
| Education | $60.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $147.92 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $118.59 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $118.59 | 7 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $58.86 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $43.98 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $43.98 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.99 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $33.84 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $28.75 | 1 | 2025 |
Source payment records
|
|||||
| NEUROSTAR TMS THERAPY SYSTEM Normalized: neurostar tms therapy system |
Device | Neuronetics, Inc. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 382 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 232 | 78 |
| Gabapentin | Gabapentin | 200 | 60 |
| Omeprazole | Omeprazole | 194 | 55 |
| Losartan Potassium | Losartan Potassium | 189 | 58 |
| Lisinopril | Lisinopril | 185 | 60 |
| Metformin Hcl | Metformin Hcl | 183 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 174 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | 50 |
| Alendronate Sodium | Alendronate Sodium | 123 | 39 |
| Trazodone Hcl | Trazodone Hcl | 117 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 33 |
| Metformin Hcl Er | Metformin Hcl | 87 | 31 |
| Simvastatin | Simvastatin | 84 | 28 |
| Furosemide | Furosemide | 82 | 31 |
| Eliquis | Apixaban | 81 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 26 |
| Potassium Chloride | Potassium Chloride | 76 | 26 |
| Mounjaro | Tirzepatide | 74 | 21 |
| Celecoxib | Celecoxib | 72 | 26 |
| Montelukast Sodium | Montelukast Sodium | 71 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | 29 |
| Pregabalin | Pregabalin | 69 | 25 |
| Bupropion Xl | Bupropion Hcl | 65 | 19 |
| Clonazepam | Clonazepam | 64 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 21 |
| Sertraline Hcl | Sertraline Hcl | 58 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 16 |
| Ozempic | Semaglutide | 56 | 14 |
| Tramadol Hcl | Tramadol Hcl | 52 | 25 |
| Jardiance | Empagliflozin | 47 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 16 |
| Azithromycin | Azithromycin | 41 | 40 |
| Prednisone | Prednisone | 41 | 39 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 41 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 38 |
| Allopurinol | Allopurinol | 38 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 12 |
| Alprazolam | Alprazolam | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 13 |
| Farxiga | Dapagliflozin Propanediol | 35 | 13 |
| Cephalexin | Cephalexin | 32 | 27 |
| Glimepiride | Glimepiride | 32 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 12 |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 28 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 13 |
| Famotidine | Famotidine | 26 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 12 |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 17 |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Atenolol | Atenolol | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Ramipril | Ramipril | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $695.79 · 37 records | ABBVIE INC. | AREXVY, CAPVAXIVE, Doc Band, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, Kerendia, NEUROSTAR TMS THERAPY SYSTEM, QULIPTA, Qelbree, SAPIEN 3 Ultra RESILIA, SHINGRIX, UBRELVY, VOQUEZNA, VRAYLAR, WATCHMAN FLX, YUPELRI, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error